These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 3910219)
41. Evaluation of mouse lip mucosa reactions after combinations of cis-diammine-1,1-cyclobutanedicarboxylate platinum (II) (CBDCA) and irradiation: single and fractionated treatments. Landuyt W; Keizer J; Chin A; van der Schueren E Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1367-70. PubMed ID: 3305448 [TBL] [Abstract][Full Text] [Related]
42. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Nonclercq D; Toubeau G; Laurent G; Tulkens PM; Heuson-Stiennon JA Exp Mol Pathol; 1989 Oct; 51(2):123-40. PubMed ID: 2680578 [TBL] [Abstract][Full Text] [Related]
43. Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study. Hannemann J; Baumann K Arch Toxicol; 1990; 64(5):393-400. PubMed ID: 2169720 [TBL] [Abstract][Full Text] [Related]
44. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459 [TBL] [Abstract][Full Text] [Related]
45. Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Begg AC; van der Kolk PJ; Emondt J; Bartelink H Radiother Oncol; 1987 Jun; 9(2):157-65. PubMed ID: 3303163 [TBL] [Abstract][Full Text] [Related]
46. In vivo toxicity of cisplatin and carboplatin on the Leydig cell function and effect of the human choriogonadotropin. Azouri H; Bidart JM; Bohuon C Biochem Pharmacol; 1989 Feb; 38(4):567-71. PubMed ID: 2644935 [TBL] [Abstract][Full Text] [Related]
47. Antitumor activity of a new platinum complex, 2-aminomethyl-pyrrolidine (1, 1-cyclobutanedicarboxylato) platinum (II). Endoh K; Akamatsu K; Matsumoto T; Morikawa K; Honda M; Mitsui H; Koizumi M; Koizumi K; Matsuno T Anticancer Res; 1989; 9(4):987-91. PubMed ID: 2817826 [TBL] [Abstract][Full Text] [Related]
48. [Antitumor activity of a new platinum complex (R)-(-)-2-aminomethylpyrrolidine (1,1-cyclobutane dicarboxylato) platinum (II) (DWA2114R) by its serial administration]. Akamatsu K; Endo K; Matsumoto T; Kamisango K; Morikawa K; Koizumi M; Mitsui H; Koizumi K; Matsuno T Gan To Kagaku Ryoho; 1989 May; 16(5):2039-43. PubMed ID: 2658840 [TBL] [Abstract][Full Text] [Related]
49. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats]. Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932 [TBL] [Abstract][Full Text] [Related]
50. Criteria for the selection of second-generation platinum compounds. Shepherd R; Kusnierczyk H; Jones M; Harrap KR Br J Cancer; 1980 Nov; 42(5):668-76. PubMed ID: 7193043 [TBL] [Abstract][Full Text] [Related]
51. [Toxic effect of cisplatin and certain platinum complexes of the 2d generation (CHIP, oxoplatina) on the gastrointestinal tract in rats]. Filipová M; Srámek B; Kvĕtina J Bratisl Lek Listy; 1986 Jan; 85(1):49-53. PubMed ID: 3955396 [No Abstract] [Full Text] [Related]
52. Chromosomal aberrations, sister chromatid exchange (SCEs) and micronuclei induction with three platinum compounds (cis-DDP, CHIP, CBDCA) in V79 cells in vitro. Plesková I; Blasko M; Siracký J Neoplasma; 1984; 31(6):655-9. PubMed ID: 6395027 [TBL] [Abstract][Full Text] [Related]
53. The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin. Chibber R; Ord MJ Eur J Cancer Clin Oncol; 1989 Jan; 25(1):27-33. PubMed ID: 2646132 [TBL] [Abstract][Full Text] [Related]
54. [Acute and subacute toxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in laboratory rodents]. Härtl A; Güttner J; Horn U; Jelinek F; Stöckel U; Schröer HP; Hoffmann H Arch Geschwulstforsch; 1989; 59(4):239-44. PubMed ID: 2640563 [TBL] [Abstract][Full Text] [Related]
55. Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Olivi A; Gilbert M; Duncan KL; Corden B; Lenartz D; Brem H Cancer Chemother Pharmacol; 1993; 31(6):449-54. PubMed ID: 8453683 [TBL] [Abstract][Full Text] [Related]
56. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150 [TBL] [Abstract][Full Text] [Related]
58. [Antitumor activity of mixed cis-complexes of platinum(II) with ammonia and cycloalkylamines]. Konovalova AL; Presnov MA; Chel'tsov PA; Kravchenko AN; Ivanov VB Dokl Akad Nauk SSSR; 1985; 281(1):200-3. PubMed ID: 4039648 [No Abstract] [Full Text] [Related]
59. Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats. Ueda T; Yasumasu T; Uozumi J J Toxicol Sci; 1991 Aug; 16(3):101-9. PubMed ID: 1942134 [TBL] [Abstract][Full Text] [Related]
60. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]